2680 related articles for article (PubMed ID: 16959725)
1. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
2. Office management of peripheral arterial disease.
Aronow WS
Am J Med; 2010 Sep; 123(9):790-2. PubMed ID: 20800143
[TBL] [Abstract][Full Text] [Related]
3. Peripheral arterial disease: a review of disease awareness and management.
Watson K; Watson BD; Pater KS
Am J Geriatr Pharmacother; 2006 Dec; 4(4):365-79. PubMed ID: 17296541
[TBL] [Abstract][Full Text] [Related]
4. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events.
Coppola G; Novo S
Arch Med Res; 2007 Jul; 38(5):479-88. PubMed ID: 17560452
[TBL] [Abstract][Full Text] [Related]
5. Optimal risk factor modification and medical management of the patient with peripheral arterial disease.
Chi YW; Jaff MR
Catheter Cardiovasc Interv; 2008 Mar; 71(4):475-89. PubMed ID: 18307227
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
Tschudi MR; Noll G; Lüscher TP
Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
[TBL] [Abstract][Full Text] [Related]
7. How optimal is the medical management of patients prior to major reconstructive vascular surgery? The results of a cross-sectional study.
Marshall C; Lin PH; Huynh TT; Kougias P
Vasc Endovascular Surg; 2009; 43(3):238-43. PubMed ID: 19190039
[TBL] [Abstract][Full Text] [Related]
8. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation.
Bianchi C; Montalvo V; Ou HW; Bishop V; Abou-Zamzam AM
Ann Vasc Surg; 2007 Mar; 21(2):163-6. PubMed ID: 17349357
[TBL] [Abstract][Full Text] [Related]
10. Peripheral arterial disease in women.
Aronow WS
Maturitas; 2009 Dec; 64(4):204-11. PubMed ID: 19853389
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
Blinc A; Poredos P
Eur J Clin Invest; 2007 Mar; 37(3):157-64. PubMed ID: 17359482
[TBL] [Abstract][Full Text] [Related]
12. Therapy insight: peripheral arterial disease and diabetes--from pathogenesis to treatment guidelines.
Mohler ER
Nat Clin Pract Cardiovasc Med; 2007 Mar; 4(3):151-62. PubMed ID: 17330127
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy before and after revascularization: anticoagulation, antiplatelet agents, and statins.
Dagher NN; Modrall JG
Semin Vasc Surg; 2007 Mar; 20(1):10-4. PubMed ID: 17386359
[TBL] [Abstract][Full Text] [Related]
14. Intensive statin therapy for Indians: Part-I. Benefits.
Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
[TBL] [Abstract][Full Text] [Related]
15. [The best of vascular medicine in 2006].
Mounier-Vehier C; Stephan D; Aboyans V; Beregi JP; Lacroix P; Léger P; Long A; Sevestre MA;
Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():47-55. PubMed ID: 17405565
[TBL] [Abstract][Full Text] [Related]
16. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
[TBL] [Abstract][Full Text] [Related]
17. Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease.
Sigvant B; Wiberg-Hedman K; Bergqvist D; Rolandsson O; Wahlberg E
Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):39-46. PubMed ID: 19237996
[TBL] [Abstract][Full Text] [Related]
18. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
Høgh AL
Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
[TBL] [Abstract][Full Text] [Related]
19. [Medical treatment of patients with clinical peripheral arterial disease at hospital discharge: compliance with the French guidelines and changing practices (COPART I registry)].
Béraut E; Cambou JP; Guilhem JM; Vaysse N; Labro S; Séverac D; Boccalon H; Bura-Rivière A
J Mal Vasc; 2008 Feb; 33(1):1-11. PubMed ID: 18187280
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.
Bi Y; Gao R; Patel A; Su S; Gao W; Hu D; Huang D; Kong L; Qi W; Wu Y; Yang Y; Turnbull F;
Am Heart J; 2009 Mar; 157(3):509-516.e1. PubMed ID: 19249422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
